Results 41 to 50 of about 2,432,871 (350)
European Respiratory Review, 2013 2011 to 2012 has seen an explosion in published research in the field of pulmonary vascular disease, especially pulmonary hypertension. In conjunction with this research has been an explosion in clinical interest in treating pulmonary hypertension. This is possible because we now have three different generic classes of drug therapy: endothelin receptor
openaire +3 more sources
Pulmonary Circulation, 2019 A 36-year-old woman presented with recurrent pulmonary emboli (PE) despite oral anticoagulation. She was a type I diabetic with severe gastroparesis requiring insertion of multiple long-term peripherally inserted central catheters (PICC) over a 10-year ...
Abigail Masding +10 more
doaj +1 more source
Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties [PDF]
, 2011 Reduced NO levels due to the deficiency of tetrahydrobiopterin (BH4) contribute to impaired vasodilation in pulmonary hypertension Due to the chemically unstable nature of BH4 it was hypothesised that oxidatively stable analogues of BR, would be able to ...
Gibson, Colin +4 more
core +1 more source
Pulmonary hypertension associated with left-sided heart disease
Swiss Medical Weekly, 2017 Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence of pulmonary hypertension is typically a marker of more advanced disease,
Micha T. Maeder +5 more
doaj +1 more source
Effects of novel muscarinic M3 receptor ligand C1213 in pulmonary arterial hypertension models. [PDF]
, 2016 Pulmonary hypertension (PH) is a complex disease comprising a pathologic remodeling and thickening of the pulmonary vessels causing an after load on the right heart ventricle that can result in ventricular failure. Triggered by oxidative stress, episodes
Ahmed, Mohamed +5 more
core +2 more sources
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
Science Translational Medicine, 2020 ACTRIIA-Fc, an activin and GDF8/11 ligand trap, improves hemodynamics and exerts antiremodeling effects in experimental pulmonary hypertension. Remedying pulmonary vascular remodeling Alterations in bone morphogenetic protein, growth and differentiation ...
L. Yung +20 more
semanticscholar +1 more source
American Journal of Respiratory and Critical Care Medicine, 2015 Pulmonary hypertension is said to occur when the mean pulmonary arterial pressure exceeds 25 mmHg at rest or 30 mmHg during exercise. There are many causes but the term Pulmonary arterial hypertension (PAH) is used to describe a rare group of illnesses that share histopathological similarities in the small muscularised pulmonary arterioles leading to ...
Ali Ataya, Johan Barretto, John Wynne
openaire +4 more sources
Pulmonary Circulation, 2020 This systematic review of literature and online reports critically appraised incidence and prevalence estimates of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension to identify the most accurate estimates.
L. Leber, A. Beaudet, A. Muller
semanticscholar +1 more source
The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients
BMC Pulmonary Medicine, 2019 Background Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH).
Iain Armstrong +6 more
doaj +1 more source
Under pressure: pulmonary hypertension associated with left heart disease. [PDF]
, 2015 © ERS 2015.Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood.
Farber, HW, Gibbs, S
core +2 more sources